RxDoctor Payments Data

Paul Derose, MD

Radiation Oncology · Richardson, TXNPI 1659573780

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,500 of the $37,195 with a category attached, or 84.7%. Novocure GmbH accounts for 60.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $25,610 and has fallen 98.7% since, to $335 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,195in general payments, 2019–2025

Across 80 payments — averaging $464.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure GmbH$23K
  • Novocure Inc.$13K
  • AstraZeneca$284
  • Sirtex Medical Inc$117
  • Medtronic$94
  • AbbVie$86
  • plus $660 from 21 others
$97,450in research payments, 2019–2025

Across 24 payments — averaging $4060.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$68K
  • Novocure Inc.$30K

What the payments were for

  • Consulting fees$31,50085%
  • Speaking & faculty fees$2,5057%
  • Food & beverage$3,1909%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,195 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas

Medicare billing

Part B allowed, 2024
$216,803
Medicare patients
208
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl40$412
Dexamethasone65$407

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →